How translational modeling in oncology needs to get the mechanism just right

Area of Science:

• Pharmacology
• Translational oncology
• Computational biology

Background:

• Translational model-based approaches have improved anticancer drug development but significant gaps remain in translating findings from animal models to human patients.
• Current optimization of drug dose and scheduling (regimen) primarily relies on clinical investigations, often after initial nonclinical studies.
• There is a need for improved methods to bridge the gap between preclinical data and clinical outcomes in cancer therapy.

Purpose of the Study:

• To advocate for the use of pragmatic mechanism-based translational modeling of nonclinical data to optimize anticancer drug regimens.
• To demonstrate a prototype model that incorporates fundamental mechanisms relevant to drug efficacy and toxicity.
• To reduce translational uncertainty in the development of novel anticancer treatments.

Main Methods:

• Utilizing mechanism-based translational modeling.
• Analyzing nonclinical data to inform drug regimen optimization.
• Developing a prototype model to address key biological and pharmacological mechanisms.

Main Results:

• A prototype mechanism-based translational model was developed.
• The model demonstrates the potential to inform anticancer drug regimen optimization.
• The approach addresses fundamental mechanisms crucial for predicting clinical outcomes.

Conclusions:

• Pragmatic mechanism-based translational modeling offers a valuable tool to enhance the optimization of anticancer drug regimens.
• This modeling approach can help reduce the uncertainty in translating preclinical findings to clinical efficacy and safety.
• Further development and application of such models can accelerate the delivery of more effective anticancer therapies to patients.